Latest news
Nearly 9 in 10 people choosing Lenacapavir are first-time users of long-acting HIV prevention | TygerBurger - novanews.co.zanovanews.co.za · Fri, 07 Aug 2026 08:20:17 GMTSingle HIV Pill Could Simplify Treatment for Drug-Resistant Patients - EMJEMJ · Thu, 06 Aug 2026 08:53:58 GMTGilead raises full-year guidance on 8% Q2 sales growth, eyes three near-term regulatory approvals - AllSciAllSci · Wed, 05 Aug 2026 14:17:35 GMTRacial, Age Inequities Evident in Lenacapavir PrEP Uptake - MedscapeMedscape · Wed, 05 Aug 2026 10:55:20 GMTAIDS 2026: Rising Above to Meet the Moment - avac.orgavac.org · Wed, 05 Aug 2026 07:00:00 GMTGilead’s Yeztugo beats forecasts as HIV PrEP franchise exceeds $1B - Endpoints NewsEndpoints News · Wed, 05 Aug 2026 01:21:00 GMTMitchell Warren says 3M lenacapavir goal falls short | AIDS 2026 - Managed Healthcare ExecutiveManaged Healthcare Executive · Sat, 01 Aug 2026 01:32:34 GMTHIV prevention drug could reduce cases globally but USAID cuts prevent access, say experts - The GuardianThe Guardian · Fri, 31 Jul 2026 16:54:00 GMT